Deng Tanggang, Xiao Yugang, Dai Yi, Xie Lin, Li Xiong
Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance, Guangdong Pharmaceutical University, Guangzhou, China.
Front Mol Biosci. 2021 Dec 15;8:743376. doi: 10.3389/fmolb.2021.743376. eCollection 2021.
Prostate cancer (PCa) is a top-incidence malignancy, and the second most common cause of death amongst American men and the fifth leading cause of cancer death in men around the world. Androgen receptor (AR), the key transcription factor, is critical for the progression of PCa by regulating a series of target genes by androgen stimulation. A number of co-regulators of AR, including co-activators or co-repressors, have been implicated in AR-mediated gene transcription and PCa progression. Epigenetic regulators, by modifying chromatin integrity and accessibility for transcription regulation without altering DNA sequences, influence the transcriptional activity of AR and further regulate the gene expression of AR target genes in determining cell fate, PCa progression and therapeutic response. In this review, we summarized the structural interaction of AR and epigenetic regulators including histone or DNA methylation, histone acetylation or non-coding RNA, and functional synergy in PCa progression. Importantly, epigenetic regulators have been validated as diagnostic markers and therapeutic targets. A series of epigenetic target drugs have been developed, and have demonstrated the potential to treat PCa alone or in combination with antiandrogens.
前列腺癌(PCa)是一种高发性恶性肿瘤,是美国男性中第二大常见死因,也是全球男性癌症死亡的第五大主要原因。雄激素受体(AR)作为关键转录因子,通过雄激素刺激调节一系列靶基因,对前列腺癌的进展至关重要。包括共激活因子或共抑制因子在内的许多AR共调节因子,都与AR介导的基因转录和前列腺癌进展有关。表观遗传调节因子通过改变染色质完整性和转录调控的可及性来影响AR的转录活性,而不改变DNA序列,并在决定细胞命运、前列腺癌进展和治疗反应中进一步调节AR靶基因的基因表达。在本综述中,我们总结了AR与表观遗传调节因子(包括组蛋白或DNA甲基化、组蛋白乙酰化或非编码RNA)的结构相互作用,以及在前列腺癌进展中的功能协同作用。重要的是,表观遗传调节因子已被验证为诊断标志物和治疗靶点。一系列表观遗传靶向药物已被开发出来,并已证明单独或与抗雄激素联合治疗前列腺癌的潜力。